KPMG Report Finds Life Sciences Firms Scaling AI Beyond Pilots Into Production Environments

Scaled AI deployment in life sciences manufacturing is no longer a roadmap item, the KPMG Global Tech Report 2026 finds that life sciences firms have moved decisively from controlled pilots into production-scale adoption, with direct implications for GMP-governed workflows, batch release automation, and quality management system architecture.

The shift carries operational weight for plant heads and QA directors. AI embedded in production environments must perform within validated states, meaning any scaled deployment triggers process validation obligations under 21 CFR Part 211 and ICH Q10 quality system principles. Change control packages, risk assessments, and CAPA frameworks will need to account for model drift, retraining cycles, and algorithm versioning in ways that legacy QMS structures were not designed to handle.

For regulatory affairs leads, the compliance read is equally direct. Regulators including the FDA and EMA have signalled increasing scrutiny of AI-assisted decision-making in manufacturing and release testing. Firms scaling AI into batch disposition or in-process monitoring without corresponding updates to their validation master plans and site master files are likely to encounter inspection findings. The gap between technical deployment speed and documentation readiness is where most risk currently sits.

The report does not specify which AI application categories are seeing the fastest uptake, but the broader industry pattern points to predictive quality analytics, automated visual inspection, and real-time release testing as the primary vectors. Each carries distinct sterility assurance and data integrity considerations under 21 CFR Part 11 and Annex 11 frameworks.

For manufacturers operating across multiple sites, the governance question is whether AI models validated at one facility can be transferred to another without full revalidation, a question that current regulatory guidance has not resolved cleanly, and one that KPMG's findings suggest is becoming urgent at scale.

The measurable checkpoint ahead is how quickly quality systems documentation catches up with the deployment curve the report describes.

Source: Indian Pharma Post via Media4Growth, 16 June 2026.